Just to chime in a bit on the sales growth, most new prescription releases have a sort of "hockey stick" type of growth pattern. The slopes obviously vary with the overall acceptance, but there is the sort of "trial" period that (I think) Ariella and yosi referring to with the samples and the prescribed use by innovators and early adopters, and then the bolus of use increases based on the early results. Hopefully we'll have a "hockey stick" with a sharp angle <G>. Of course, some of this depends on Bausch & Lomb, but they need the revenue too.
There are obviously exceptions to this, Viagra and nicotine patches were huge at the beginning, with nicotine patches eventually leveling off to their predicted market size. Viagra looks like a behemoth though. Those two products were a little different though. They were like "consumer pharmaceuticals" really, geared towards someone going in and asking for a drug for a specific need. AIDS treatment was different as well because those people are dying, and just about anything that can help is being used, but I'm rambling . . .
I think that given Pharmos' plan to design to minimize side effects, the drugs that they develop stand a good chance of being very well accepted and garnering good market share if they are successful in that part of their drug development. That's why I own the stock. Hope we are all correct.
Filbert |
